Celldex Therapeutics, Inc. financial data

Symbol
CLDX on Nasdaq
Location
Hampton, NJ
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 25 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1527% % -40%
Debt-to-equity 7.2% % 59%
Return On Equity -42% % -110%
Return On Assets -39% % -105%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 66,566,346 shares 0.28%
Common Stock, Shares, Outstanding 66,549,442 shares 0.26%
Entity Public Float $1,300,000,000 USD -46%
Common Stock, Value, Issued $67,000 USD 1.5%
Weighted Average Number of Shares Outstanding, Basic 66,422 shares 3.1%
Weighted Average Number of Shares Outstanding, Diluted 66,422 shares 3.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $5,791,000 USD -30%
Research and Development Expense $245,074,000 USD 50%
General and Administrative Expense $43,838,000 USD 14%
Costs and Expenses $288,912,000 USD 43%
Operating Income (Loss) $287,367,000 USD -47%
Net Income (Loss) Attributable to Parent $258,757,000 USD -64%
Earnings Per Share, Basic -3.9 USD/shares -59%
Earnings Per Share, Diluted -3.9 USD/shares -59%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $28,871,000 USD 1.8%
Marketable Securities, Current $489,702,000 USD -30%
Assets, Current $534,664,000 USD -28%
Property, Plant and Equipment, Net $5,334,000 USD 23%
Operating Lease, Right-of-Use Asset $2,437,000 USD -37%
Intangible Assets, Net (Excluding Goodwill) $27,190,000 USD 0%
Other Assets, Noncurrent $13,358,000 USD 37%
Assets $582,983,000 USD -26%
Accounts Payable, Current $1,180,000 USD -64%
Employee-related Liabilities, Current $11,811,000 USD 2.1%
Accrued Liabilities, Current $47,029,000 USD 39%
Liabilities, Current $50,991,000 USD 29%
Operating Lease, Liability, Noncurrent $784,000 USD -67%
Other Liabilities, Noncurrent $4,043,000 USD 16%
Liabilities $55,818,000 USD 23%
Accumulated Other Comprehensive Income (Loss), Net of Tax $3,626,000 USD 9.4%
Retained Earnings (Accumulated Deficit) $1,813,981,000 USD -17%
Stockholders' Equity Attributable to Parent $527,165,000 USD -29%
Liabilities and Equity $582,983,000 USD -26%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $54,372,000 USD -34%
Net Cash Provided by (Used in) Financing Activities $202,000 USD -100%
Net Cash Provided by (Used in) Investing Activities $42,950,000 USD
Common Stock, Shares Authorized 297,000,000 shares 0%
Common Stock, Shares, Issued 66,549,442 shares 0.26%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $11,220,000 USD -114%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $28,871,000 USD 1.8%
Deferred Tax Assets, Valuation Allowance $374,505,000 USD 17%
Deferred Tax Assets, Gross $380,402,000 USD 17%
Operating Lease, Liability $2,336,000 USD -39%
Payments to Acquire Property, Plant, and Equipment $265,000 USD -23%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $258,445,000 USD -64%
Lessee, Operating Lease, Liability, to be Paid $2,509,000 USD -41%
Property, Plant and Equipment, Gross $29,238,000 USD 5.1%
Operating Lease, Liability, Current $1,552,000 USD 6.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two $804,000 USD -55%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,705,000 USD -3.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $173,000 USD -63%
Lessee, Operating Lease, Liability, to be Paid, Year Three $742,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $245,763,000 USD 39%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 3,000,000 shares 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $867,000 USD 12%
Share-based Payment Arrangement, Expense $36,217,000 USD 5.8%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%